Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company UpdatesGlobeNewsWire • 08/01/24
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 07/30/24
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong BuyZacks Investment Research • 07/11/24
BlueAllele Corporation Files Lawsuit for Patent Infringement against Intellia Therapeutics, Inc., for the Unauthorized Use of BlueAllele's Patented Bi-directional Insertion TemplatesBusiness Wire • 07/08/24
Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law FirmPRNewsWire • 07/02/24
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024The Motley Fool • 07/02/24
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery PlatformGlobeNewsWire • 06/25/24
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024InvestorPlace • 06/21/24